RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Addeo, A; Miranda-Morales, E; den Hollander, P; Friedlaender, A; Sintim, HO; Wu, J; Mani, SA; Subbiah, V

Subbiah, V (通讯作者),Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, PhaseClin Trials Program 1, Div Canc Med,Unit 455, 1515 Holcombe Blvd, Houston, TX 77030 USA.

PHARMACOLOGY & THERAPEUTICS, 2023; 242 ():